Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of legubicin + osimertinib in EGFR-mutant non-squamous non-small cell lung cancer after failure of third-generation EGFR-TKI therapy
CTR20262987Phase 2Active
- Sponsor
- Shanghai Qinheli Biotechnology
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lecubicin, osimertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Qinheli Biotechnology. Started Aug 2026; status: active.
02
Drugs
lecubicinosimertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20262987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262987.